The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.
BACKGROUND
Vascular risk factors (VRF) may influence response to rivastigmine in Alzheimer's disease (AD).


METHODS
AD patients who participated in a randomized, double-blind, placebo-controlled trial of rivastigmine patch and capsule treatment were stratified by baseline VRF status. Treatment response was evaluated using the AD Assessment Scale-cognitive subscale (ADAS-cog), AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale.


RESULTS
ADAS-cog scores significantly improved in all rivastigmine-treated patients (p < 0.05 vs. placebo), except 9.5 mg/24 h patch-treated patients with VRF, and were significantly affected by VRF status in the study population as a whole. Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF. The ADCS-CGIC significantly improved in capsule-treated patients with, and patch-treated patients without VRF. Although non-significant, patients without VRF showed an apparent faster rate of placebo decline.


CONCLUSION
VRF may influence AD progression and response to rivastigmine.
['Farlow|M R|MR|', 'Doraiswamy|P M|PM|', 'Meng|X|X|', 'Cooke|K|K|', 'Somogyi|M|M|']
Vascular risk factors Efficacy Rivastigmine Alzheimer's disease Transdermal patch